S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
Stop Trading Like A Turtle (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Stop Trading Like A Turtle (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Stop Trading Like A Turtle (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
Stop Trading Like A Turtle (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Stop Trading Like A Turtle (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Stop Trading Like A Turtle (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
Stop Trading Like A Turtle (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Stop Trading Like A Turtle (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Stop Trading Like A Turtle (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
Stop Trading Like A Turtle (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Stop Trading Like A Turtle (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Stop Trading Like A Turtle (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
NASDAQ:LPTX

Leap Therapeutics (LPTX) Stock Forecast, Price & News

$0.89
+0.08 (+9.88%)
(As of 05/31/2023 ET)
Compare
Today's Range
$0.79
$0.91
50-Day Range
$0.29
$0.89
52-Week Range
$0.27
$1.86
Volume
1.67 million shs
Average Volume
852,446 shs
Market Capitalization
$106.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.80

Leap Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
214.6% Upside
$2.80 Price Target
Short Interest
Bearish
9.65% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of Leap Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.57) to ($0.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

833rd out of 1,006 stocks

Pharmaceutical Preparations Industry

416th out of 492 stocks


LPTX stock logo

About Leap Therapeutics (NASDAQ:LPTX) Stock

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

Receive LPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LPTX Stock News Headlines

Leap Therapeutics (LPTX) Receives a Buy from Mizuho Securities
We Called (ARWR) In Advance, Which Stocks Are Next?
Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.
We Called (ARWR) In Advance, Which Stocks Are Next?
Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.
Leap Therapeutics, Inc. (NASDAQ:LPTX) Short Interest Update
What 5 Analyst Ratings Have To Say About Leap Therapeutics
Leap Therapeutics (NASDAQ:LPTX) Announces Earnings Results
Mizuho Securities Remains a Buy on Leap Therapeutics (LPTX)
Robert W. Baird Keeps Their Buy Rating on Leap Therapeutics (LPTX)
Leap Therapeutics, Inc. (LPTX)
See More Headlines
Receive LPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LPTX Company Calendar

Last Earnings
5/15/2023
Today
5/31/2023
Next Earnings (Estimated)
8/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LPTX
Fax
N/A
Employees
36
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.80
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+214.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-54,600,000.00
Pretax Margin
-14,214.93%

Debt

Sales & Book Value

Annual Sales
$1.50 million
Book Value
$0.24 per share

Miscellaneous

Free Float
104,485,000
Market Cap
$106.27 million
Optionable
Not Optionable
Beta
0.74

Key Executives

  • Doug E. Onsi
    President, CEO, CFO, Secretary & Treasurer
  • Augustine J. Lawlor
    Chief Operating Officer
  • Cynthia Sirard
    Chief Medical Officer
  • Jason S. Baum
    Chief Scientific Officer
  • Michael Haas
    Head-Research













LPTX Stock - Frequently Asked Questions

Should I buy or sell Leap Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LPTX shares.
View LPTX analyst ratings
or view top-rated stocks.

What is Leap Therapeutics' stock price forecast for 2023?

3 brokerages have issued 12 month price targets for Leap Therapeutics' shares. Their LPTX share price forecasts range from $2.00 to $4.00. On average, they expect the company's stock price to reach $2.80 in the next twelve months. This suggests a possible upside of 214.6% from the stock's current price.
View analysts price targets for LPTX
or view top-rated stocks among Wall Street analysts.

How have LPTX shares performed in 2023?

Leap Therapeutics' stock was trading at $0.45 at the beginning of the year. Since then, LPTX shares have increased by 97.8% and is now trading at $0.89.
View the best growth stocks for 2023 here
.

When is Leap Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our LPTX earnings forecast
.

How were Leap Therapeutics' earnings last quarter?

Leap Therapeutics, Inc. (NASDAQ:LPTX) issued its quarterly earnings results on Monday, May, 15th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.23.

What other stocks do shareholders of Leap Therapeutics own?
What is Leap Therapeutics' stock symbol?

Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."

Who are Leap Therapeutics' major shareholders?

Leap Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Baker BROS. Advisors LP (6.22%), Samsara BioCapital LLC (5.61%), Price T Rowe Associates Inc. MD (1.29%), Key Client Fiduciary Advisors LLC (1.29%), Knott David M Jr (0.47%) and Renaissance Technologies LLC (0.38%).
View institutional ownership trends
.

How do I buy shares of Leap Therapeutics?

Shares of LPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Leap Therapeutics' stock price today?

One share of LPTX stock can currently be purchased for approximately $0.89.

How much money does Leap Therapeutics make?

Leap Therapeutics (NASDAQ:LPTX) has a market capitalization of $106.27 million and generates $1.50 million in revenue each year. The company earns $-54,600,000.00 in net income (profit) each year or ($0.71) on an earnings per share basis.

How can I contact Leap Therapeutics?

Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The official website for the company is www.leaptx.com. The company can be reached via phone at (617) 714-0360 or via email at heather@argotpartners.com.

This page (NASDAQ:LPTX) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -